Beruflich Dokumente
Kultur Dokumente
Jeffrey Henderson
Cardiac Glycosides
October 17, 2012
Sarah Johnson Maya Hamam Barret Barr Divya Prajapati
Family of compounds derived from the Digitalis plant (Digitalis purpurea or Digitalis lanata)
Types
Cardiac glycosides are cardiotonic drugs Used in the treatment of congestive heart failure and cardiac arrhythmia
Digitoxin
Digoxin
Decompensation contractions get weaker In heart failure: - Decompensation occurs well below the pericardium limit
Increase contractile strength of failing heart by 50-100% Drugs have little effect on a healthy heart
Mechanism of Action
Mechanism of Action
Signs: Biphasic / inversions of T-wave in ECG Uneven depolarization in parts of the ventricle
DIGIBIND
Drug-Drug Interactions
Quinidine
Itraconazole
Propafenone Verapamil
Amiodarone Indomethacin
Antibiotics:
Azithromycin
Telithromycin Erythromycin Clarithromycin Tetracycline
Decreased renal clearance and increased bioavailability due to Pglycoprotein inhibition Destruction of gut bacteria capable of metabolizing Digitalis Inhibition of CYP3a4 metabolism in liver
Summary
Cardiac glycosides are a family of compounds derived from the digitalis plant Digitalis consists of two major cardiac glycosides: Digitoxin and Digoxin. Cardiac Glycosides partially inhibit the E2 Na+/K+ ATPase by preventing dephosphorylation. This causes Na+ to accumulate inside the cell, inhibiting NCX and causes VOCC to open. The rise in Ca+2 induces SR to release Ca+2 which results in a stronger contraction of the ventricle. Overdose results in complete inhibition of the Na+/K+ pump no membrane repolarization no muscle relaxation heart stops beating! Adverse reactions of Digoxin normally only occur at doses higher than those needed to achieve a therapeutic effects. Massive overdoses of Digoxin can be reversed using DIGIBIND, a drug that binds to Digoxin molecules making them unavailable for biding at their site of action in the body There are three main mechanisms that can make Digitalis concentrations potentially toxic. 1) inhibition of P-glycoprotein transporter in the kidneys 2) eradication of gut bacteria that metabolize Digitalis 3) inhibition of Cyp3A metabolism in the liver.
References
eCPS
Guyton, A.C. and J.E. Hall. 2006. Electrocardiographic Interpretation of Cardiac Muscle and Coronary Blood Flow Abnormalities: Vectorial Analysis., p. 146, 261-263. In W. Schmitt and R. Gruliow, Textbook of Medical Physiology, Elsevier Saunders, Philadelphia.
Schwartz, A., Whitner, K., Grupp, G., Grupp, I., Adams, R., and S. Lee. 1982. Mechanism of Action Digitalis: Is the Na,K-ATPase The Pharmacological Receptor?. Annals New York Academy of Sciences, 82, 253-271. Winnicka K., Belawski K., Bielawska A., 2006. Cardiac Glycosides in Cancer Research and Cancer Therapy. Acta Poloniae Pharmaceutica n Drug Research. Vol. 63 No. 2 pp. 109-115 Wood, C. and C. Nurse. 2011. Bio 3U03 Animal Physiology:Homeostasis Term I. Cardiac Physiology., Lecture 5 p. 4. McMaster Uni.